Luteolytic Agents

Chemical compounds that cause LUTEOLYSIS or degeneration of the CORPUS LUTEUM.

Also Known As:

Luteolytic Effect; Luteolytic Effects; Agent, Luteolytic; Agents, Luteolytic; Effect, Luteolytic; Effects, Luteolytic; Luteolytic Agent

Networked: 10 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Therapeutic Uses: 47080
    - Reproductive Control Agents
      - Contraceptive Agents: 6494
        Hormonal Contraceptive Agents: 7
        Luteolytic Agents: 10
        Female Contraceptive Agents: 5
        Luteolytic Agents: 10
      - Luteolytic Agents: 10
  - Physiological Effects of Drugs: 1
    - Reproductive Control Agents
      - Contraceptive Agents: 6494
        Hormonal Contraceptive Agents: 7
        Luteolytic Agents: 10
        Female Contraceptive Agents: 5
        Luteolytic Agents: 10
      - Luteolytic Agents: 10

Experts

1.	Hu, Xiaokun: 1 article (01/2017)
2.	Huang, Kejun: 1 article (01/2017)
3.	Luo, Yingyi: 1 article (01/2017)
4.	Mai, Qingyun: 1 article (01/2017)
5.	Yang, Gang: 1 article (01/2017)
6.	Yuan, Yuan: 1 article (01/2017)
7.	Zhou, Canquan: 1 article (01/2017)
8.	Bonilla-Musoles, F M: 1 article (01/2009)
9.	Castillo, J C: 1 article (01/2009)
10.	Dolz, M: 1 article (01/2009)

Related Diseases

1.	Cysts 02/01/2004 - "Treatment with a luteolytic agent, prostaglandin F2alpha (PGF2alpha), is successful if a luteal cyst is diagnosed properly. " 11/01/1983 - "Sixty-two dairy cows diagnosed as having cystic ovarian degeneration were used to study the correlation between rectal palpation findings and plasma progesterone concentrations and the response of cysts to treatment using fenprostalene, a luteolytic agent. "
2.	Ovarian Hyperstimulation Syndrome 01/01/2009 - "To determine whether treatment of severe ovarian hyperstimulation syndrome (OHSS) with high-dose gonadotropin-releasing hormone (GnRH) antagonist, due to its luteolytic effect, is an effective method of management. " 01/01/2017 - "Our results indicate that ovarian hyperstimulation syndrome might be caused through a luteolytic effect rather than through modulation of vascular endothelial growth factor, racing by a decline in estradiol and termination of early-onset ovarian hyperstimulation syndrome in advance in high-risk women with cryopreservation of the whole embryos."
3.	Uterine Hemorrhage (Uterine Bleeding) 01/01/1975 - "Twenty-five milligrams of prostaglandin F2alpha (PGF2alpha) was administered intravenously at selected times during the luteal phase to demonstrate a luteolytic effect, or a local effect upon the endometrium producing early vaginal bleeding. " 01/01/1975 - "Careful comparison of hormone levels and clinical details in these cycles showed that a) 1000 IU HCG daily does not consistently prolong the luteal phase; b) 2500 IU HCG daily does significantly prolong the luteal phase; c) HCG administration significantly increases progesterone and estradiol output in the treated luteal phase; d) prostaglandin administration at selected times during the luteal phase does not consistently decrease estradiol or progesterone output from the corpus luteum or induce early vaginal bleeding; e) prostaglandin F2alpha, a known stimulant of uterine contractility probably causes vaginal bleeding by mechanical means, as evidenced by show of menses in patients with progesterone levels elevated above normal; f) although variations in progesterone and estradiol output occurred during the hours of prostaglandin infusion, no consistent change was observed except for a compensatory rebound in progesterone output; g) prostaglandin F2alpha, in the dose utilized, is not a luteolytic agent."
4.	Uterine Diseases (Endometrial Disease) 01/01/1997 - "In general, the luteolytic effect of low PGF2 alpha doses was insufficient because of the recovery of the corpora lutea seen in nearly all bitches and the prolonged process of embryonic or fetal resorption that increase the risk of uterine disease."
5.	Ulcer 01/01/1992 - "Our results show that CIPG, administered at higher doses than those inducing an luteolytic effect, has a gastroprotective effect both in the contention stress-induced ulcer (2.30 + 0.26 in series III as compared to 3.80 +/- 0.73 in series III, p < 0.01) and in indomethacin-induced ulcer (2.69 +/- 0.38 in series V as compared to 3.61 +/- 0.34 in series IV, p < 0.01)."

Related Drugs and Biologics

1.	Progesterone
2.	fenprostalene
3.	Dinoprost
4.	Estradiol (Delestrogen)
5.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
6.	Quinacrine (Mepacrine)
7.	Prostaglandins
8.	Gonadotropin-Releasing Hormone (GnRH)
9.	Indomethacin (Indometacin)
10.	Hormones (Hormone)